Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.66 CAD
−26.93 M CAD
77.57 M CAD
31.06 M
About HLS Therapeutics, Inc.
Sector
Industry
CEO
Craig Millian
Website
Headquarters
Etobicoke
Founded
2014
ISIN
CA40390B1094
FIGI
BBG000BXJ2X3
HLS Therapeutics, Inc. engages in commercializing pharmaceutical products. It specializes in central nervous system and cardiovascular markets. The company was founded by Gregory Gubitz and Gilbert Godin on June 5, 2014 and is headquartered in Etobicoke, Canada.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on TSX exchange HLS Therapeutics, Inc. stocks are traded under the ticker HLS.
We've gathered analysts' opinions on HLS Therapeutics, Inc. future price: according to them, HLS price has a max estimate of 9.64 CAD and a min estimate of 5.07 CAD. Watch HLS chart and read a more detailed HLS Therapeutics, Inc. stock forecast: see what analysts think of HLS Therapeutics, Inc. and suggest that you do with its stocks.
Yes, you can track HLS Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
HLS Therapeutics, Inc. is going to release the next earnings report on Nov 6, 2025. Keep track of upcoming events with our Earnings Calendar.
HLS earnings for the last quarter are −0.12 CAD per share, whereas the estimation was −0.10 CAD resulting in a −20.43% surprise. The estimated earnings for the next quarter are −0.09 CAD per share. See more details about HLS Therapeutics, Inc. earnings.
HLS Therapeutics, Inc. revenue for the last quarter amounts to 19.29 M CAD, despite the estimated figure of 19.74 M CAD. In the next quarter, revenue is expected to reach 20.06 M CAD.
HLS net income for the last quarter is −3.79 M CAD, while the quarter before that showed −6.36 M CAD of net income which accounts for 40.40% change. Track more HLS Therapeutics, Inc. financial stats to get the full picture.
As of Oct 28, 2025, the company has 92 employees. See our rating of the largest employees — is HLS Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HLS Therapeutics, Inc. EBITDA is 23.17 M CAD, and current EBITDA margin is 26.55%. See more stats in HLS Therapeutics, Inc. financial statements.
Like other stocks, HLS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HLS Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.